Related Experiment Video
Updated: Jul 31, 2025
A Mouse Model for Laser-induced Choroidal Neovascularization
Published on: December 27, 2015
Attenuation of Laser-Induced Choroidal Neovascularization by Blockade of Prostaglandin D2 Receptor 2
Hirotsugu Soga1, Tatsuya Inoue2, Yoshihiro Urade1,3
1Department of Ophthalmology, University of Tokyo Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan.
Purpose:
The purpose of this study was to investigate the impact of prostaglandin D2 (PGD2) receptor 2 (DP2) on choroidal neovascularization (CNV) formation in mice.
Methods:
Using a laser-induced CNV model, the CNV size of wild-type (WT) mice treated with DP2 antagonist (CAY10471 or OC000459) was compared with that of untreated mice. Vascular endothelial growth factor (VEGF) and MCP-1 levels were also compared between the two groups. Similar experiments were performed comparing DP2 knockout (DP2KO) mice with WT mice (8 and 56 weeks old). The number of infiltrating macrophages to laser spots was also compared between the WT and DP2KO mice. We administered a DP2 antagonist to 15-methyl PGD2 (a DP2 agonist)-stimulated ARPE-19 cells and measured VEGF secretion by enzyme-linked immunosorbent assay. Tube formation assay was performed on human umbilical vein endothelial cells with or without a DP2 antagonist.
Results:
CNV sizes were significantly smaller in mice treated with CAY10471 or OC000459 than in those treated with vehicle. Similarly, the CNV size of DP2KO mice was significantly smaller than that of WT mice. The number of macrophages at laser spots in DP2KO mice was significantly lower than that in WT mice. The VEGF concentration of lasered DP2KO mice's eyes was significantly lower than that of lasered WT mice' eyes. DP2 antagonist treatment suppressed VEGF secretion in ARPE-19 cells under 15-methyl PGD2 stimulation. The tube formation assay suggested that lumen formation was inhibited by a DP2 antagonist.
Conclusions:
DP2 blockade attenuated choroidal neovascularization.
Translational Relevance:
Drugs targeting DP2 are potentially a novel treatment for age-related macular degeneration.
Insights
Blocking prostaglandin D2 receptor 2 (DP2) significantly reduced choroidal neovascularization (CNV) in mice. This suggests DP2 antagonists may offer a new treatment for age-related macular degeneration.
Area of Science:
- Ophthalmology
- Immunology
- Pharmacology
Background:
- Choroidal neovascularization (CNV) is a key factor in age-related macular degeneration.
- Prostaglandin D2 receptor 2 (DP2) is implicated in inflammatory processes.
- Understanding DP2's role in CNV is crucial for developing new therapies.
Purpose of the Study:
- To investigate the impact of prostaglandin D2 receptor 2 (DP2) on choroidal neovascularization (CNV) formation.
- To evaluate the therapeutic potential of DP2 antagonists in a mouse model of CNV.
Main Methods:
- A laser-induced CNV model in wild-type (WT) and DP2 knockout (DP2KO) mice.
- Administration of DP2 antagonists (CAY10471, OC000459) to WT mice.
- Comparison of CNV size, VEGF, MCP-1 levels, and macrophage infiltration between groups.
- In vitro studies using ARPE-19 cells and human umbilical vein endothelial cells.
Main Results:
- DP2 antagonist treatment and DP2 knockout significantly reduced CNV size compared to controls.
- Macrophage infiltration and VEGF levels were lower in DP2-deficient or blocked conditions.
- DP2 antagonist inhibited VEGF secretion in ARPE-19 cells and impaired endothelial tube formation.
Conclusions:
- DP2 blockade effectively attenuates choroidal neovascularization.
- Targeting DP2 presents a promising novel therapeutic strategy for age-related macular degeneration.
Related Concept Videos
01:28Angle Closure Glaucoma: Treatment
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...